**NM signifies a non meaningful value. A dash signifies the data is not available.

Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

AbbVie (NYSE:ABBV) shares snap seven straight sessions of losses, as the stock ended 0.71% higher at $202.72 on Thursday. The biopharmaceutical company lost nearly 6% in the preceding seven ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and valleys. Even if there’s a city off in the distance to your right, it does ...

Ross, M.D., Ph.D., vice president, early oncology research and development, AbbVie. “By harnessing the latest scientific breakthroughs in translational research, we are advancing novel therapeutic ...

Ross, M.D., Ph.D., vice president, early oncology research and development, AbbVie. "By harnessing the latest scientific breakthroughs in translational research, we are advancing novel therapeutic ...

AbbVie‘s stock took a nosedive on March 25, dropping 3.25% and landing at $202.37 during mid-day trading. This left the stock 7.45% below its 52-week high and raised eyebrows on Wall Street. Analysts ...

AbbVie (ABBV) closed the most recent trading day at $209.17, moving -0.4% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.77%. At the same time ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the theft of trade secrets. Genmab has vowed to “vigorously defend ...